Headache education in Africa: a narrative review of educational programs, clinical practice implications, and policy opportunities - Report - MDSpire

Headache education in Africa: a narrative review of educational programs, clinical practice implications, and policy opportunities

  • By

  • Nicholas Aderinto

  • Thomas Oyediran

  • Emmanuela Ojoagefu Egwu

  • Emmanuel Kodizuru Chukwuemeka

  • Meron Yitna Teshome

  • Oluwafisayo Tosin Olasupo

  • Faith Adedayo Adejumo

  • July 8, 2026

  • 0 min

Share

Educational Initiatives for Headache Management in Africa: A Comprehensive Review

Background

Headache disorders are highly prevalent and disabling, yet they are often under-recognized and inadequately treated in Africa. The continent faces unique challenges, including cultural stigma, limited access to specialists, and insufficient training for frontline healthcare providers.

Data Highlights

No numerical data provided in the source material.

Key Findings

  • Headache disorders affect nearly 3 billion people globally, with significant disability attributed to migraines.
  • A systematic review estimated migraine prevalence in Africa at approximately 5.6%, affecting nearly 56 million individuals.
  • Educational initiatives like the EHHPA symposium have improved diagnostic confidence and knowledge among healthcare providers.
  • Task-shifting to non-physician clinicians and community health workers is feasible and effective in headache management.
  • Culturally responsive approaches and engagement with traditional healers are essential for equitable healthcare delivery.

Clinical Implications

Healthcare providers in Africa should prioritize education on headache disorders to improve diagnosis and management. Collaborative efforts involving traditional healers and community health workers can enhance access to care and reduce stigma associated with headaches.

Conclusion

Enhancing educational initiatives is vital for addressing the substantial headache burden in Africa. Continued investment in training and culturally sensitive approaches will be essential for improving headache care across the continent.

Related Resources & Content

  1. Author(s)/Org, Source, Year -- Title
  2. IHS, ACP Differ on Migraine Tx, conexiant, 2024
  3. Connecting the Dots: Molecular Mechanisms, Regional Activity, and Neural Connectivity in Headache Disorders, Brain, 2024
  4. Glaucoma Physician — Glaucoma in Africa
  5. WHO Fact Sheet on Headache Disorders
  6. International Headache Society - ICHD Resources
  7. WHO EML 23rd List (2023)
  8. Intersectoral global
  9. International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine - Francesca Puledda, Simona Sacco, Hans-Christoph Diener, Messoud Ashina, Haidar M. Al-Khazali, Sait Ashina, Rami Burstein, Eric Liebler, Andrea Cipriani, Min Kyung Chu, Alexandra Cocores, Freda Dodd-Glover, Esme Ekizoğlu, David Garcia-Azorin, Carl H. Göbel, Maria Teresa Goicochea, Amr Hassan, Koichi Hirata, Jan Hoffmann, Bronwyn Jenkins, Katharina Kamm, Mi Ji Lee, Yu-Hsiang Ling, Marco Lisicki, Daniele Martinelli, Teshamae S. Monteith, Raffaele Ornello, Aynur Özge, Mario Fernando Prieto Peres, Patricia Pozo-Rosich, Volodymyr Romanenko, Todd J. Schwedt, Marcio Nattan P Souza, Tsubasa Takizawa, Gisela M. Terwindt, Janu Thuraiaiyah, Mansoureh Togha, Nicolas Vandenbussche, Shuu-Jiun Wang, Shenguan Yu, Cristina Tassorelli, 2024
  10. IHS Position statement on setting higher standards for migraine prevention published - International Headache Society
  11. 2025 guideline update to acute treatment of migraine for adults in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies - Robblee - 2026 - Headache: The Journal of Head and Face Pain - Wiley Online Library
  12. The Regional Outreach Programme of the International Headache Society: A WHO IGAP-oriented initiative in partnership with DREAM to improve healthcare for people with headache in Sub-Saharan Africa
  13. e-Learning Hub: EHHPA
  14. New treatments for migraine: CGRP monoclonal antibodies, gepants, and ditans
  15. Efficacy and Safety of Anti-CGRP Monoclonal Antibodies for Chronic Migraine with Medication Overuse: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (P12-12.008) | Neurology
  16. Unveiling the efficacy and safety of Erenumab, a monoclonal antibody targeting calcitonin gene-related peptide (CGRP) receptor, in patients with chronic and episodic migraine: a GRADE-assessed systematic review and meta-analysis of randomized clinical trials with subgroup analysis | Head & Face Medicine | Springer Nature Link
  17. Frontiers | Comprehensive preventive treatments for episodic migraine: a systematic review of randomized clinical trials
  18. Increased infection risk in patients on preventive CGRP-targeting therapies– a meta-analysis and clinical effect assessment | The Journal of Headache and Pain | Springer Nature Link

Original Source(s)

Related Content